Glenmark Pharmaceuticals S.a.

Glenmark Pharmaceuticals Limited

Daisy Manish Shah

Abraham Thomas

Neelima Khairatkar-Joshi

Malini Bajpai

Sanjib Das

Shailesh Ramesh Pardeshi

Laxmikant Atmaram Gharat

Rajendra L Harde

Sandeep Y Shelke

Sachin Sundarlal Chaudhari

Balasubramanian Gopalan

V S Prasada Rao Lingam

Gopalan Balasubramanian

Dnyaneshwar E Shelke

Abhay Kulkarni

Vikram Mansingh Bhosale

Ashok Bhausaheb Kadam

Sachin Vasantrao Dhone

V S Prasadarao Lingam

Vishal Govindrao Deshmukh

Vs Prasada Rao Lingam

Alamelu Mangai Thiraviam

Bhavik Jaysukhlal Lodhiya

Prashant Dilip Wadekar

Megha Marathe

Avinash Annaso Hadambar

Bharat G Adik

Neelima Khairatkar-joshi

Rajendra Laxman Harde

Sandeep Yadunath Shelke

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R, R, R, R, R, R, R, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

Compounds as ROR gamma modulators

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R, R, R, R, R, R, R, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer. 

The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

Carbocyclic compounds as ROR gamma modulators

The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer. 

The present patent application relates to treatment of a respiratory disorder using retinoid-related orphan receptor gamma t (ROR-gamma) modulators. Particularly, the present patent application relates to treatment of a respiratory disorder using a ROR&#x3b3; inhibitor, wherein the ROR&#x3b3; inhibitor is administered by an inhalation route to a subject in need thereof.

Treatment of respiratory disorders using ROR-gamma inhibitors

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R, R, R, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer. 

Aryl and heteroaryl ether compounds as ROR gamma modulators

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X, X, M, R, R, R, R, m, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, neurodegenerative diseases and cancer. 

Bicyclic heteroaryl indole analogues useful as ROR gamma modulators

The present invention relates to novel compounds useful as dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula: wherein X, Y, a, R, and Rare as defined herein.

Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them

The present invention relates to novel dipeptidyl peptidase IV (DPP-IV) inhibitors their analogs, isomers, pharmaceutical compositions, therapeutic uses and methods of making the same.

Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof

Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation

Growing community of inventors

Mumbai, India

Daisy Manish Shah